Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Parkinson's Disease

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 192 articles:
HTML format
Text format



Single Articles


    February 2018
  1. WEISS D, Massano J
    Approaching adaptive control in neurostimulation for Parkinson disease: Autopilot on.
    Neurology. 2018 Feb 14. pii: WNL.0000000000005111.
    PubMed     Text format    


  2. ARLOTTI M, Marceglia S, Foffani G, Volkmann J, et al
    Eight-hours adaptive deep brain stimulation in patients with Parkinson disease.
    Neurology. 2018 Feb 14. pii: WNL.0000000000005121.
    PubMed     Text format     Abstract available


  3. HONMA M, Masaoka Y, Kuroda T, Futamura A, et al
    Impairment of cross-modality of vision and olfaction in Parkinson disease.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005110.
    PubMed     Text format     Abstract available


    January 2018
  4. MURATA M, Odawara T, Hasegawa K, Iiyama S, et al
    Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized, double-blind phase 2 study.
    Neurology. 2018 Jan 24. pii: WNL.0000000000005010.
    PubMed     Text format     Abstract available


  5. HERSHEY LA, Irwin DJ
    Zonisamide for DLB parkinsonism: An old drug used in a new context.
    Neurology. 2018 Jan 24. pii: WNL.0000000000005006.
    PubMed     Text format    


  6. LEE PC, Ahmed I, Loriot MA, Mulot C, et al
    Smoking and Parkinson disease: Evidence for gene-by-smoking interactions.
    Neurology. 2018 Jan 19. pii: WNL.0000000000004953.
    PubMed     Text format     Abstract available


  7. DAVIS JL, Kurek JA, Morgan JC, Sethi KD, et al
    Teaching Video NeuroImages: Oculogyric crisis in treated Parkinson disease.
    Neurology. 2018;90:e263.
    PubMed     Text format    


  8. MUNOZ DG, Fujioka S
    Caffeine and Parkinson disease: A possible diagnostic and pathogenic breakthrough.
    Neurology. 2018 Jan 3. pii: WNL.0000000000004898.
    PubMed     Text format    


  9. FUJIMAKI M, Saiki S, Li Y, Kaga N, et al
    Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease.
    Neurology. 2018 Jan 3. pii: WNL.0000000000004888.
    PubMed     Text format     Abstract available


    December 2017
  10. BARTHEL C, Nonnekes J, van Helvert M, Haan R, et al
    The laser shoes: A new ambulatory device to alleviate freezing of gait in Parkinson disease.
    Neurology. 2017 Dec 20. pii: WNL.0000000000004795.
    PubMed     Text format     Abstract available


  11. ROSSO AL, Bohnen NI, Launer LJ, Aizenstein HJ, et al
    Vascular and dopaminergic contributors to mild parkinsonian signs in older adults.
    Neurology. 2017 Dec 15. pii: WNL.0000000000004842.
    PubMed     Text format     Abstract available


  12. MELE B, Holroyd-Leduc J, Smith EE, Pringsheim T, et al
    Detecting anxiety in individuals with Parkinson disease: A systematic review.
    Neurology. 2017 Dec 6. pii: WNL.0000000000004771.
    PubMed     Text format     Abstract available


  13. FERRER P, Montoya J, Garcia Ruiz PJ
    Teaching NeuroImages: A rare case of giant perivascular spaces in the midbrain manifesting as atypical parkinsonism.
    Neurology. 2017;89:e272-e273.
    PubMed     Text format    


  14. BROCKMANN K, Lerche S, Dilger SS, Stirnkorb JG, et al
    SNPs in Abeta clearance proteins: Lower CSF Abeta1-42 levels and earlier onset of dementia in PD.
    Neurology. 2017;89:2335-2340.
    PubMed     Text format     Abstract available


  15. DAHODWALA N, Shah K, He Y, Wu SS, et al
    Sex disparities in access to caregiving in Parkinson disease.
    Neurology. 2017 Dec 1. pii: WNL.0000000000004764.
    PubMed     Text format     Abstract available


    November 2017
  16. CENTI J, Freeman R, Gibbons CH, Neargarder S, et al
    Author response: Effects of orthostatic hypotension on cognition in Parkinson disease.
    Neurology. 2017;89:2122.
    PubMed     Text format    


  17. GUARALDI P, Poda R, Calandra-Buonaura G, Solieri L, et al
    Letter re: Effects of orthostatic hypotension on cognition in Parkinson disease.
    Neurology. 2017;89:2122.
    PubMed     Text format    


  18. DODEL R
    beta-Amyloid pathology and Parkinson disease.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004756.
    PubMed     Text format    


  19. WHITWELL JL, Weigand SD, Duffy JR, Clark HM, et al
    Predicting clinical decline in progressive agrammatic aphasia and apraxia of speech.
    Neurology. 2017 Nov 1. pii: 10.1212/WNL.0000000000004685.
    PubMed     Text format     Abstract available


    October 2017
  20. CUMMING K, Macleod AD, Myint PK, Counsell CE, et al
    Early weight loss in parkinsonism predicts poor outcomes: Evidence from an incident cohort study.
    Neurology. 2017 Oct 27. pii: 10.1212/WNL.0000000000004691.
    PubMed     Text format     Abstract available


  21. MOLLENHAUER B, Caspell-Garcia CJ, Coffey CS, Taylor P, et al
    Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.
    Neurology. 2017 Oct 13. pii: 10.1212/WNL.0000000000004609.
    PubMed     Text format     Abstract available


  22. UC EY, Rizzo M, O'Shea AMJ, Anderson SW, et al
    Longitudinal decline of driving safety in Parkinson disease.
    Neurology. 2017 Oct 11. pii: 10.1212/WNL.0000000000004629.
    PubMed     Text format     Abstract available


  23. TABUAS-PEREIRA M, Santana I, Santo GC
    Clinical Reasoning: A 55-year-old man with rapidly progressive dementia and parkinsonism.
    Neurology. 2017;89:e182-e187.
    PubMed     Text format    


  24. BRODSKY MA, Anderson S, Murchison C, Seier M, et al
    Clinical outcomes of asleep vs awake deep brain stimulation for Parkinson disease.
    Neurology. 2017 Oct 6. pii: 10.1212/WNL.0000000000004630.
    PubMed     Text format     Abstract available


  25. AZIZ TZ, Hariz M
    To sleep or not to sleep during deep brain stimulation surgery for Parkinson disease?
    Neurology. 2017 Oct 6. pii: 10.1212/WNL.0000000000004635.
    PubMed     Text format    


    September 2017
  26. LEEHEY M, Luo S, Sharma S, Wills AA, et al
    Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores.
    Neurology. 2017 Sep 29. pii: 10.1212/WNL.0000000000004572.
    PubMed     Text format     Abstract available


  27. HEDERA P, Davis TL
    Can lifestyle modification slow progression of Parkinson disease?
    Neurology. 2017 Sep 29. pii: 10.1212/WNL.0000000000004580.
    PubMed     Text format    


  28. POSTUMA RB, Anang J, Pelletier A, Joseph L, et al
    Caffeine as symptomatic treatment for Parkinson disease (Cafe-PD): A randomized trial.
    Neurology. 2017 Sep 27. pii: 10.1212/WNL.0000000000004568.
    PubMed     Text format     Abstract available


  29. MOREAU C, Barton BR, Devos D
    Virtually reducing fall risk in Parkinson disease.
    Neurology. 2017 Sep 27. pii: 10.1212/WNL.0000000000004581.
    PubMed     Text format    


  30. MAIDAN I, Rosenberg-Katz K, Jacob Y, Giladi N, et al
    Disparate effects of training on brain activation in Parkinson disease.
    Neurology. 2017 Sep 27. pii: 10.1212/WNL.0000000000004576.
    PubMed     Text format     Abstract available


  31. THORMANN A, Sorensen PS, Koch-Henriksen N, Laursen B, et al
    Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality.
    Neurology. 2017 Sep 20. pii: 10.1212/WNL.0000000000004508.
    PubMed     Text format     Abstract available


  32. SHAMIR R, Klein C, Amar D, Vollstedt EJ, et al
    Analysis of blood-based gene expression in idiopathic Parkinson disease.
    Neurology. 2017 Sep 15. pii: 10.1212/WNL.0000000000004516.
    PubMed     Text format     Abstract available


  33. LECLAIR-VISONNEAU L, Clairembault T, Coron E, Le Dily S, et al
    REM sleep behavior disorder is related to enteric neuropathology in Parkinson disease.
    Neurology. 2017 Sep 8. pii: 10.1212/WNL.0000000000004496.
    PubMed     Text format     Abstract available


  34. BOWMAN GL
    Biomarkers for early detection of Parkinson disease: A scent of consistency with olfactory dysfunction.
    Neurology. 2017 Sep 6. pii: 10.1212/WNL.0000000000004383.
    PubMed     Text format    


  35. CHEN H, Shrestha S, Huang X, Jain S, et al
    Olfaction and incident Parkinson disease in US white and black older adults.
    Neurology. 2017 Sep 6. pii: 10.1212/WNL.0000000000004382.
    PubMed     Text format     Abstract available


  36. SEARLES NIELSEN S, Warden MN, Camacho-Soto A, Willis AW, et al
    A predictive model to identify Parkinson disease from administrative claims data.
    Neurology. 2017 Sep 1. pii: 10.1212/WNL.0000000000004536.
    PubMed     Text format     Abstract available


    August 2017
  37. FULLARD ME, Thibault DP, Hill A, Fox J, et al
    Utilization of rehabilitation therapy services in Parkinson disease in the United States.
    Neurology. 2017 Aug 23. pii: 10.1212/WNL.0000000000004355.
    PubMed     Text format     Abstract available


  38. NOLANO M, Provitera V, Manganelli F, Iodice R, et al
    Loss of cutaneous large and small fibers in naive and l-dopa-treated PD patients.
    Neurology. 2017;89:776-784.
    PubMed     Text format     Abstract available


  39. SHPRECHER DR, Majersik JJ
    The virtual house call: A 21st-century innovation in the care of patients with Parkinson disease.
    Neurology. 2017 Aug 16. pii: 10.1212/WNL.0000000000004366.
    PubMed     Text format    


  40. BECK CA, Beran DB, Biglan KM, Boyd CM, et al
    National randomized controlled trial of virtual house calls for Parkinson disease.
    Neurology. 2017 Aug 16. pii: 10.1212/WNL.0000000000004357.
    PubMed     Text format     Abstract available


  41. VERHAGEN METMAN L, Espay AJ
    Teaching Video NeuroImages: The underrecognized diphasic dyskinesia of Parkinson disease.
    Neurology. 2017;89:e83-e84.
    PubMed     Text format    


  42. CURY RG, Fraix V, Castrioto A, Perez Fernandez MA, et al
    Thalamic deep brain stimulation for tremor in Parkinson disease, essential tremor, and dystonia.
    Neurology. 2017 Aug 2. pii: 10.1212/WNL.0000000000004295.
    PubMed     Text format     Abstract available


    July 2017
  43. REGENSBURGER M, Turk M, Pagenstecher A, Schroder R, et al
    VCP-related multisystem proteinopathy presenting as early-onset Parkinson disease.
    Neurology. 2017 Jul 19. pii: 10.1212/WNL.0000000000004240.
    PubMed     Text format    


  44. IRANZO A, Stefani A, Serradell M, Marti MJ, et al
    Characterization of patients with longstanding idiopathic REM sleep behavior disorder.
    Neurology. 2017;89:242-248.
    PubMed     Text format     Abstract available


  45. JACOVA C, Factor SA
    Phosphodiesterase 4: Rethinking cognition in Parkinson disease.
    Neurology. 2017 Jul 12. pii: 10.1212/WNL.0000000000004221.
    PubMed     Text format    


  46. NICCOLINI F, Wilson H, Pagano G, Coello C, et al
    Loss of phosphodiesterase 4 in Parkinson disease: Relevance to cognitive deficits.
    Neurology. 2017 Jul 12. pii: 10.1212/WNL.0000000000004201.
    PubMed     Text format     Abstract available


  47. SIERRA M, Martinez-Rodriguez I, Sanchez-Juan P, Gonzalez-Aramburu I, et al
    Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease.
    Neurology. 2017 Jul 5. pii: 10.1212/WNL.0000000000004185.
    PubMed     Text format     Abstract available


  48. CILIA R, Laguna J, Cassani E, Cereda E, et al
    Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study.
    Neurology. 2017 Jul 5. pii: 10.1212/WNL.0000000000004175.
    PubMed     Text format     Abstract available



  49. Decrease in Abeta42 predicts dopa-resistant gait progression in early Parkinson disease.
    Neurology. 2017;89:107.
    PubMed     Text format    


    June 2017
  50. HUGHES KC, Gao X, Kim IY, Wang M, et al
    Intake of dairy foods and risk of Parkinson disease.
    Neurology. 2017 Jun 8. pii: 10.1212/WNL.0000000000004057.
    PubMed     Text format     Abstract available


  51. RAJPUT AH, Rajput ML, Ferguson LW, Rajput A, et al
    Baseline motor findings and Parkinson disease prognostic subtypes.
    Neurology. 2017 Jun 7. pii: 10.1212/WNL.0000000000004078.
    PubMed     Text format     Abstract available


    May 2017
  52. MARKOVIC V, Agosta F, Canu E, Inuggi A, et al
    Role of habenula and amygdala dysfunction in Parkinson disease patients with punding.
    Neurology. 2017 May 10. pii: 10.1212/WNL.0000000000004012.
    PubMed     Text format     Abstract available


  53. STOCCHI F, Rascol O, Hauser RA, Huyck S, et al
    Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.
    Neurology. 2017 May 10. pii: 10.1212/WNL.0000000000004003.
    PubMed     Text format     Abstract available


    April 2017
  54. LIU B, Fang F, Pedersen NL, Tillander A, et al
    Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study.
    Neurology. 2017 Apr 26. pii: 10.1212/WNL.0000000000003961.
    PubMed     Text format     Abstract available


  55. BORGHAMMER P, Hamani C
    Preventing Parkinson disease by vagotomy: Fact or fiction?
    Neurology. 2017 Apr 26. pii: 10.1212/WNL.0000000000003969.
    PubMed     Text format    


    March 2017
  56. PAKPOOR J, Noyce A, Goldacre R, Selkihova M, et al
    Viral hepatitis and Parkinson disease: A national record-linkage study.
    Neurology. 2017 Mar 29. pii: 10.1212/WNL.0000000000003848.
    PubMed     Text format     Abstract available


  57. BENITO-LEON J
    Viral hepatitis and the risk of Parkinson disease.
    Neurology. 2017 Mar 29. pii: 10.1212/WNL.0000000000003853.
    PubMed     Text format    


  58. ROCHESTER L, Galna B, Lord S, Yarnall AJ, et al
    Decrease in Abeta42 predicts dopa-resistant gait progression in early Parkinson disease.
    Neurology. 2017 Mar 22. pii: 10.1212/WNL.0000000000003840.
    PubMed     Text format     Abstract available


  59. SINGER W, Berini SE, Sandroni P, Fealey RD, et al
    Pure autonomic failure: Predictors of conversion to clinical CNS involvement.
    Neurology. 2017;88:1129-1136.
    PubMed     Text format     Abstract available


  60. NONNEKES J, Janssen S, Bloem BR
    Superficial brain stimulation to overcome freezing of gait in Parkinson disease.
    Neurology. 2017 Mar 15. pii: 10.1212/WNL.0000000000003859.
    PubMed     Text format    


  61. SAARI L, Kivinen K, Gardberg M, Joutsa J, et al
    Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease.
    Neurology. 2017 Mar 10. pii: 10.1212/WNL.0000000000003810.
    PubMed     Text format     Abstract available


    February 2017
  62. BUCHMAN AS, Bennett DA
    Author response: Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2017;88:920.
    PubMed     Text format    


  63. BOHNEN NI, Muller M
    Letter re: Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2017;88:920.
    PubMed     Text format    


  64. BUCHMAN AS, Bennett DA
    Author response: Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2017;88:919-920.
    PubMed     Text format    


  65. MAHLKNECHT P, Kiechl S, Willeit J, Poewe W, et al
    Letter re: Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2017;88:919.
    PubMed     Text format    


  66. GOLDMAN JG, Bledsoe IO, Merkitch D, Dinh V, et al
    Corpus callosal atrophy and associations with cognitive impairment in Parkinson disease.
    Neurology. 2017 Feb 24. pii: 10.1212/WNL.0000000000003764.
    PubMed     Text format     Abstract available


  67. MERY VP, Gros P, Lafontaine AL, Robinson A, et al
    Reduced cognitive function in patients with Parkinson disease and obstructive sleep apnea.
    Neurology. 2017 Feb 22. pii: 10.1212/WNL.0000000000003738.
    PubMed     Text format     Abstract available


  68. LEWITT PA, Li J, Lu M, Guo L, et al
    Metabolomic biomarkers as strong correlates of Parkinson disease progression.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003663.
    PubMed     Text format     Abstract available


  69. ALVES G, Bonanni L
    Neurofilament light: A heavyweight diagnostic biomarker in neurodegenerative parkinsonism?
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003699.
    PubMed     Text format    


  70. HANSSON O, Janelidze S, Hall S, Magdalinou N, et al
    Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003680.
    PubMed     Text format     Abstract available


    January 2017
  71. EWENCZYK C, Mesmoudi S, Gallea C, Welter ML, et al
    Antisaccades in Parkinson disease: A new marker of postural control?
    Neurology. 2017 Jan 27. pii: 10.1212/WNL.0000000000003658.
    PubMed     Text format     Abstract available


  72. PEDERSEN KF, Larsen JP, Tysnes OB, Alves G, et al
    Natural course of mild cognitive impairment in Parkinson disease: A 5-year population-based study.
    Neurology. 2017 Jan 20. pii: 10.1212/WNL.0000000000003634.
    PubMed     Text format     Abstract available


  73. FEDOROVA TD, Seidelin LB, Knudsen K, Schacht AC, et al
    Decreased intestinal acetylcholinesterase in early Parkinson disease: An 11C-donepezil PET study.
    Neurology. 2017 Jan 18. pii: 10.1212/WNL.0000000000003633.
    PubMed     Text format     Abstract available


  74. KUBU CS, Cooper SE, Machado A, Frazier T, et al
    Insights gleaned by measuring patients' stated goals for DBS: More than tremor.
    Neurology. 2017;88:124-130.
    PubMed     Text format     Abstract available


    December 2016
  75. RACETTE BA, Searles Nielsen S, Criswell SR, Sheppard L, et al
    Dose-dependent progression of parkinsonism in manganese-exposed welders.
    Neurology. 2016 Dec 28. pii: 10.1212/WNL.0000000000003533.
    PubMed     Text format     Abstract available


  76. RATNER MH, Fitzgerald E
    Understanding of the role of manganese in parkinsonism and Parkinson disease.
    Neurology. 2016 Dec 28. pii: 10.1212/WNL.0000000000003543.
    PubMed     Text format    


  77. THOLFSEN LK, Larsen JP, Schulz J, Tysnes OB, et al
    Changes in insomnia subtypes in early Parkinson disease.
    Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003540.
    PubMed     Text format     Abstract available


    November 2016
  78. CENTI J, Freeman R, Gibbons CH, Neargarder S, et al
    Effects of orthostatic hypotension on cognition in Parkinson disease.
    Neurology. 2016 Nov 30. pii: 10.1212/WNL.0000000000003452.
    PubMed     Text format     Abstract available


  79. BOYLAN LS, Messinis L
    Orthostatic hypotension, cognition, and Parkinson disease: Dumbing down by standing up.
    Neurology. 2016 Nov 30. pii: 10.1212/WNL.0000000000003468.
    PubMed     Text format    


  80. MANO T, Britton Z, Britton T
    Anatomo-functional basis of nonmotor symptoms in Parkinson disease.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003443.
    PubMed     Text format    


  81. PYATIGORSKAYA N, Mongin M, Valabregue R, Yahia-Cherif L, et al
    Medulla oblongata damage and cardiac autonomic dysfunction in Parkinson disease.
    Neurology. 2016 Nov 11. pii: 10.1212/WNL.0000000000003426.
    PubMed     Text format     Abstract available


  82. PAGANO G, Molloy S, Bain PG, Rabiner EA, et al
    Sleep problems and hypothalamic dopamine D3 receptor availability in Parkinson disease.
    Neurology. 2016 Nov 2. pii: 10.1212/WNL.0000000000003396.
    PubMed     Text format     Abstract available


    October 2016
  83. MATTIS PJ, Niethammer M, Sako W, Tang CC, et al
    Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases.
    Neurology. 2016 Oct 5. pii: 10.1212/WNL.0000000000003285.
    PubMed     Text format     Abstract available


  84. BRYS M, Fox MD, Agarwal S, Biagioni M, et al
    Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: A randomized trial.
    Neurology. 2016 Oct 5. pii: 10.1212/WNL.0000000000003279.
    PubMed     Text format     Abstract available


    September 2016
  85. UMEMOTO G, Fujioka S, Yanamoto S, Fukae J, et al
    A case of sudden deterioration in Parkinson disease.
    Neurology. 2016;87:1422.
    PubMed     Text format    


  86. MORGANTE F, Fasano A, Ginevrino M, Petrucci S, et al
    Impulsive-compulsive behaviors in parkin-associated Parkinson disease.
    Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003177.
    PubMed     Text format     Abstract available


  87. BJORNESTAD A, Tysnes OB, Larsen JP, Alves G, et al
    Loss of independence in early Parkinson disease: A 5-year population-based incident cohort study.
    Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003213.
    PubMed     Text format     Abstract available


    August 2016
  88. QUATTRONE A, Morelli M, Williams DR, Vescio B, et al
    MR parkinsonism index predicts vertical supranuclear gaze palsy in patients with PSP-parkinsonism.
    Neurology. 2016 Aug 24. pii: 10.1212/WNL.0000000000003125.
    PubMed     Text format     Abstract available


  89. BARICHELLA M, Pacchetti C, Bolliri C, Cassani E, et al
    Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT.
    Neurology. 2016 Aug 19. pii: 10.1212/WNL.0000000000003127.
    PubMed     Text format     Abstract available


  90. SIDIROPOULOS C, LeWitt PA, Odekerken VJ, Schuurman PR, et al
    GPi vs STN deep brain stimulation for Parkinson disease: Three-year follow-up.
    Neurology. 2016;87:745-6.
    PubMed     Text format    


  91. BUCHMAN AS, Leurgans SE, Yu L, Wilson RS, et al
    Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2016 Aug 3. pii: 10.1212/WNL.0000000000003059.
    PubMed     Text format     Abstract available


    July 2016
  92. BOYD JT, Wangensteen KJ, Krawitt EL, Hamill RW, et al
    Hepatitis C virus infection as a risk factor for Parkinson disease: A nationwide cohort study.
    Neurology. 2016;87:342.
    PubMed     Text format    


  93. BURCIU RG, Chung JW, Shukla P, Ofori E, et al
    Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromes.
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000002985.
    PubMed     Text format     Abstract available



  94. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.
    Neurology. 2016;87:239.
    PubMed     Text format    


  95. JELLINGER KA, Logroscino G, Rizzo G, Copetti M, et al
    Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis.
    Neurology. 2016;87:237-8.
    PubMed     Text format    


  96. GIBBONS CH, Garcia J, Wang N, Shih LC, et al
    The diagnostic discrimination of cutaneous alpha-synuclein deposition in Parkinson disease.
    Neurology. 2016 Jul 6. pii: 10.1212/WNL.0000000000002919.
    PubMed     Text format     Abstract available


    June 2016
  97. GOODARZI Z, Mrklas KJ, Roberts DJ, Jette N, et al
    Detecting depression in Parkinson disease: A systematic review and meta-analysis.
    Neurology. 2016 Jun 29. pii: 10.1212/WNL.0000000000002898.
    PubMed     Text format     Abstract available


  98. COLLOBY SJ, McKeith IG, Burn DJ, Wyper DJ, et al
    Cholinergic and perfusion brain networks in Parkinson disease dementia.
    Neurology. 2016 Jun 15. pii: 10.1212/WNL.0000000000002839.
    PubMed     Text format     Abstract available


    May 2016
  99. OSAKI Y, Fujita K, Abe T, Harada M, et al
    Mystery Case: Parkinsonism in a diabetic uremic patient.
    Neurology. 2016;86:e225-7.
    PubMed     Text format    


  100. VAN DER HEEDEN JF, Marinus J, Martinez-Martin P, Rodriguez-Blazquez C, et al
    Postural instability and gait are associated with severity and prognosis of Parkinson disease.
    Neurology. 2016 May 13. pii: 10.1212/WNL.0000000000002768.
    PubMed     Text format     Abstract available


  101. FACTOR SA, Bennett A, Hohler AD, Wang D, et al
    Quality improvement in neurology: Parkinson disease update quality measurement set: Executive summary.
    Neurology. 2016 May 11. pii: 10.1212/WNL.0000000000002670.
    PubMed     Text format    


  102. CHAUDHURI KR
    Progression and biomarkers for Parkinson disease: Merging motor with nonmotor symptoms.
    Neurology. 2016 May 6. pii: 10.1212/WNL.0000000000002664.
    PubMed     Text format    


  103. MOLLENHAUER B, Zimmermann J, Sixel-Doring F, Focke NK, et al
    Monitoring of 30 marker candidates in early Parkinson disease as progression markers.
    Neurology. 2016 May 6. pii: 10.1212/WNL.0000000000002651.
    PubMed     Text format     Abstract available


  104. LATTANZI S, Silvestrini M, Verbeek MM, Mollenhauer B, et al
    Increased CSF biomarkers of angiogenesis in Parkinson disease.
    Neurology. 2016;86:1747-8.
    PubMed     Text format    


    April 2016
  105. BOHNEN NI, Muller ML, Sohn YH, Lee DH, et al
    Is normosmic Parkinson disease a unique clinical phenotype?
    Neurology. 2016;86:1649-50.
    PubMed     Text format    


  106. MASSANO J, Bronstein JM
    Writeclick: Neuropsychological outcome after deep brain stimulation for Parkinson disease.
    Neurology. 2016;86:1563-4.
    PubMed     Text format    


  107. LOVERA LC, Rodriguez-Porcel F, Urrea-Mendoza E, Fasano A, et al
    Flamenco dancer posture: Unique "off" complication in Parkinson disease.
    Neurology. 2016;86:1462-3.
    PubMed     Text format    


  108. LEWITT PA, Fahn S
    Levodopa therapy for Parkinson disease: A look backward and forward.
    Neurology. 2016;86.
    PubMed     Text format     Abstract available


  109. SILVER DE, Trosch RM
    Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson disease.
    Neurology. 2016;86.
    PubMed     Text format     Abstract available


  110. DHALL R, Kreitzman DL
    Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety.
    Neurology. 2016;86.
    PubMed     Text format     Abstract available


  111. GUPTA S
    Advances in levodopa therapy for Parkinson disease.
    Neurology. 2016;86.
    PubMed     Text format    


    March 2016
  112. ABE K, Bohnen NI, Muller ML, van der Holst HM, et al
    Cerebral small vessel disease and incident parkinsonism: The RUN DMC study.
    Neurology. 2016;86:1268-9.
    PubMed     Text format    


  113. BOHNEN NI, Muller ML
    Cerebral small vessel disease and incident parkinsonism: the RUN DMC study.
    Neurology. 2016;86:1268-9.
    PubMed     Text format    


  114. ABE K
    Cerebral small vessel disease and incident parkinsonism: the RUN DMC study.
    Neurology. 2016;86:1268-9.
    PubMed     Text format    



  115. Hepcidin ameliorates mitochondrial damage in a rat model of Parkinson's disease (P3.019).
    Neurology. 2016;86:1077.
    PubMed     Text format    


  116. SCHERFLER C, Gobel G, Muller C, Nocker M, et al
    Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism.
    Neurology. 2016 Mar 2. pii: 10.1212/WNL.0000000000002518.
    PubMed     Text format     Abstract available


    February 2016
  117. ROUSSAKIS AA, Politis M, Towey D, Piccini P, et al
    Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias.
    Neurology. 2016 Feb 26. pii: 10.1212/WNL.0000000000002494.
    PubMed     Text format     Abstract available


  118. VELSEBOER DC, de Bie RM, Wieske L, Evans JR, et al
    Development and external validation of a prognostic model in newly diagnosed Parkinson disease.
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002437.
    PubMed     Text format     Abstract available


  119. CHIO A, Defazio G
    A new scale for prognostication in Parkinson disease: Of animals and men.
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002435.
    PubMed     Text format    


  120. STERLING NW, Wang M, Zhang L, Lee EY, et al
    Stage-dependent loss of cortical gyrification as Parkinson disease "unfolds".
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002492.
    PubMed     Text format     Abstract available


  121. GRUNEWALD A, Klein C
    Urinary LRRK2 phosphorylation: Penetrating the thicket of Parkinson disease?
    Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002438.
    PubMed     Text format    


  122. PAGANO G, Ferrara N, Brooks DJ, Pavese N, et al
    Age at onset and Parkinson disease phenotype.
    Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002461.
    PubMed     Text format     Abstract available


  123. KEMPSTER PA
    Biomarkers for the progression of Parkinson disease.
    Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002473.
    PubMed     Text format    


  124. FRASER KB, Moehle MS, Alcalay RN, West AB, et al
    Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers.
    Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002436.
    PubMed     Text format     Abstract available


  125. ABBOTT RD, Ross GW, Petrovitch H, Masaki KH, et al
    Midlife milk consumption and substantia nigra neuron density at death.
    Neurology. 2016;86:512-9.
    PubMed     Text format     Abstract available


  126. CHEN H, Marder K
    Milk consumption and the risk of nigral degeneration.
    Neurology. 2016;86:496-7.
    PubMed     Text format    


    January 2016
  127. ODEKERKEN VJ, Boel JA, Schmand BA, de Haan RJ, et al
    GPi vs STN deep brain stimulation for Parkinson disease: Three-year follow-up.
    Neurology. 2016 Jan 27. pii: 10.1212/WNL.0000000000002401.
    PubMed     Text format     Abstract available


  128. STOESSL AJ
    Comment: Increased D3 binding-A substrate for levodopa-induced dyskinesias?
    Neurology. 2016;86:228.
    PubMed     Text format    


  129. GAO X, O'Reilly EJ, Schwarzschild MA, Ascherio A, et al
    Prospective study of plasma urate and risk of Parkinson disease in men and women.
    Neurology. 2016 Jan 13. pii: 10.1212/WNL.0000000000002351.
    PubMed     Text format     Abstract available


  130. RIZZO G, Copetti M, Arcuti S, Martino D, et al
    Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis.
    Neurology. 2016 Jan 13. pii: 10.1212/WNL.0000000000002350.
    PubMed     Text format     Abstract available


  131. KOSCHMIDDER E, Weissbach A, Bruggemann N, Kasten M, et al
    A nonsense mutation in CHCHD2 in a patient with Parkinson disease.
    Neurology. 2016 Jan 13. pii: 10.1212/WNL.0000000000002361.
    PubMed     Text format    


    December 2015
  132. PAYER DE, Guttman M, Kish SJ, Tong J, et al
    D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia.
    Neurology. 2015 Dec 30. pii: 10.1212/WNL.0000000000002285.
    PubMed     Text format     Abstract available


  133. LOHLE M, Mende J, Wolz M, Beuthien-Baumann B, et al
    Putaminal dopamine turnover in de novo Parkinson disease predicts later motor complications.
    Neurology. 2015 Dec 30. pii: 10.1212/WNL.0000000000002286.
    PubMed     Text format     Abstract available


  134. TSAI HH, Liou HH, Muo CH, Lee CZ, et al
    Hepatitis C virus infection as a risk factor for Parkinson disease: A nationwide cohort study.
    Neurology. 2015 Dec 23. pii: 10.1212/WNL.0000000000002307.
    PubMed     Text format     Abstract available


  135. HATANO T, Kurita N, Kobayashi M, Hattori N, et al
    Teaching Video NeuroImages: Re-emergent jaw tremor in Parkinson disease.
    Neurology. 2015;85:e181.
    PubMed     Text format    


    November 2015
  136. LABBE C, Ogaki K, Lorenzo-Betancor O, Soto-Ortolaza AI, et al
    Role for the microtubule-associated protein tau variant p.A152T in risk of alpha-synucleinopathies.
    Neurology. 2015;85:1680-6.
    PubMed     Text format     Abstract available


  137. WITJAS T, Carron R, Krack P, Eusebio A, et al
    A prospective single-blind study of Gamma Knife thalamotomy for tremor.
    Neurology. 2015;85:1562-8.
    PubMed     Text format     Abstract available


  138. GOLDSTEIN DS, Holmes C, Sharabi Y, Wu T, et al
    Survival in synucleinopathies: A prospective cohort study.
    Neurology. 2015;85:1554-61.
    PubMed     Text format     Abstract available


    October 2015
  139. VENTURA MI, Edwards JD, Barnes DE
    More than just a movement disorder: Why cognitive training is needed in Parkinson disease.
    Neurology. 2015 Oct 30. pii: 10.1212/WNL.0000000000002158.
    PubMed     Text format    


  140. LEUNG IH, Walton CC, Hallock H, Lewis SJ, et al
    Cognitive training in Parkinson disease: A systematic review and meta-analysis.
    Neurology. 2015 Oct 30. pii: 10.1212/WNL.0000000000002145.
    PubMed     Text format     Abstract available


  141. JANELIDZE S, Lindqvist D, Francardo V, Hall S, et al
    Increased CSF biomarkers of angiogenesis in Parkinson disease.
    Neurology. 2015 Oct 28. pii: 10.1212/WNL.0000000000002151.
    PubMed     Text format     Abstract available


  142. MUNOZ DG, Woulfe JM
    Angiogenesis: A new paradigm for Parkinson disease with practical and pathogenic implications.
    Neurology. 2015 Oct 28. pii: 10.1212/WNL.0000000000002160.
    PubMed     Text format    


  143. TINAZZI M, Fasano A, Geroin C, Morgante F, et al
    Pisa syndrome in Parkinson disease: An observational multicenter Italian study.
    Neurology. 2015 Oct 21. pii: 10.1212/WNL.0000000000002122.
    PubMed     Text format     Abstract available


  144. BRONSTEIN JM, Odekerken VJ, Boel JA, Schmand BA, et al
    Neuropsychological outcome after deep brain stimulation for Parkinson disease.
    Neurology. 2015;85:1433-4.
    PubMed     Text format    


  145. ODEKERKEN VJ, Boel JA, Schmand BA, de Bie RM, et al
    Author response.
    Neurology. 2015;85:1433-4.
    PubMed     Text format    


  146. UNGER MM, Sakakibara R
    Does REM sleep behavior disorder have the guts to be Parkinson disease?
    Neurology. 2015 Oct 16. pii: 10.1212/WNL.0000000000002130.
    PubMed     Text format    


  147. HASSAN A, Benarroch EE
    Heterogeneity of the midbrain dopamine system: Implications for Parkinson disease.
    Neurology. 2015 Oct 16. pii: 10.1212/WNL.0000000000002137.
    PubMed     Text format    


  148. IACONO D, Geraci-Erck M, Rabin ML, Adler CH, et al
    Parkinson disease and incidental Lewy body disease: Just a question of time?
    Neurology. 2015 Oct 14. pii: 10.1212/WNL.0000000000002102.
    PubMed     Text format     Abstract available


  149. VAN DER HOLST HM, van Uden IW, Tuladhar AM, de Laat KF, et al
    Cerebral small vessel disease and incident parkinsonism: The RUN DMC study.
    Neurology. 2015 Oct 7. pii: 10.1212/WNL.0000000000002082.
    PubMed     Text format     Abstract available


  150. LUCA CC, Rundek T
    Parkinsonism, small vessel disease, and white matter disease: Is there a link?
    Neurology. 2015 Oct 7. pii: 10.1212/WNL.0000000000002091.
    PubMed     Text format    


    September 2015
  151. PARK JE
    Reflections: Neurology and the Humanities. Not too late.
    Neurology. 2015;85:e88.
    PubMed     Text format    


  152. PIGOTT K, Rick J, Xie SX, Hurtig H, et al
    Longitudinal study of normal cognition in Parkinson disease.
    Neurology. 2015 Sep 11. pii: 10.1212/WNL.0000000000002001.
    PubMed     Text format     Abstract available


  153. HERSHEY LA, Peavy GM
    Cognitive decline in Parkinson disease: How steep and crowded is the slope?
    Neurology. 2015 Sep 11. pii: 10.1212/WNL.0000000000002003.
    PubMed     Text format    


  154. WANG L, Aasly JO, Annesi G, Bardien S, et al
    Large-scale assessment of polyglutamine repeat expansions in Parkinson disease.
    Neurology. 2015 Sep 9. pii: 10.1212/WNL.0000000000002016.
    PubMed     Text format     Abstract available


  155. ROSSI S, Ulivelli M
    The olfactory side of Parkinson disease: Relevance for clinical practice.
    Neurology. 2015 Sep 9. pii: 10.1212/WNL.0000000000002005.
    PubMed     Text format    


  156. LEE DH, Oh JS, Ham JH, Lee JJ, et al
    Is normosmic Parkinson disease a unique clinical phenotype?
    Neurology. 2015 Sep 9. pii: 10.1212/WNL.0000000000001999.
    PubMed     Text format     Abstract available


  157. FILLA A
    CAG repeats in idiopathic Parkinson disease: To screen or not to screen.
    Neurology. 2015 Sep 9. pii: 10.1212/WNL.0000000000002024.
    PubMed     Text format    


  158. MORTIBOYS H, Furmston R, Bronstad G, Aasly J, et al
    UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo.
    Neurology. 2015;85:846-52.
    PubMed     Text format     Abstract available


  159. HUOT P, Hutchison WD
    Serotonin/dopamine transporter ratio as a predictor of L-dopa-induced dyskinesia.
    Neurology. 2015;85:840-1.
    PubMed     Text format    


  160. RUFFMANN C, Parkkinen L, Woulfe JM, Gray MT, et al
    Colonic mucosal alpha-synuclein lacks specificity as a biomarker for Parkinson disease.
    Neurology. 2015;85:834-5.
    PubMed     Text format    


  161. VISANJI NP, Lang AE, Hazrai LN
    Author response.
    Neurology. 2015;85:834-5.
    PubMed     Text format    


  162. WOULFE JM, Gray MT, Munoz G
    Colonic mucosal alpha-synuclein lacks specificity as a biomarker for Parkinson disease.
    Neurology. 2015;85:834.
    PubMed     Text format    


    August 2015
  163. OOSTERVELD LP, Allen JC Jr, Ng EY, Seah SH, et al
    Greater motor progression in patients with Parkinson disease who carry LRRK2 risk variants.
    Neurology. 2015 Aug 26. pii: 10.1212/WNL.0000000000001953.
    PubMed     Text format     Abstract available


  164. KELLEY JM, Espay AJ, Dwivedi A, Lang AE, et al
    Placebo effect of medication cost in Parkinson disease: A randomized double-blind study.
    Neurology. 2015;85:742-3.
    PubMed     Text format    


  165. KELLEY JM
    Placebo effect of medication cost in Parkinson disease: a randomized double-blind study.
    Neurology. 2015;85:742-3.
    PubMed     Text format    


  166. XIE T, Vigil J, MacCracken E, Warnke P, et al
    Author Response.
    Neurology. 2015;85:557.
    PubMed     Text format    


  167. SIDIROPOULOS C
    Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD.
    Neurology. 2015;85:557.
    PubMed     Text format    


  168. GREENAMYRE JT, Sanders LH, Gasser T
    Fruit flies, bile acids, and Parkinson disease: A mitochondrial connection?
    Neurology. 2015 Aug 7. pii: 10.1212/WNL.0000000000001912.
    PubMed     Text format    


  169. LEE JY, Seo S, Lee JS, Kim HJ, et al
    Putaminal serotonergic innervation: Monitoring dyskinesia risk in Parkinson disease.
    Neurology. 2015 Aug 7. pii: 10.1212/WNL.0000000000001909.
    PubMed     Text format     Abstract available


  170. NIRENBERG MJ
    Preoperative factors of apathy in subthalamic stimulated Parkinson disease: A PET study.
    Neurology. 2015;85:483.
    PubMed     Text format    


  171. WORTHINGTON JM, Ney J
    The end of life with PD can be well-lived: the neurologist's role.
    Neurology. 2015;85:394-5.
    PubMed     Text format    


  172. KOGA S, Aoki N, Uitti RJ, van Gerpen JA, et al
    When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients.
    Neurology. 2015;85:404-12.
    PubMed     Text format     Abstract available


    July 2015
  173. NA YC, Chang WS, Jung HH, Kweon EJ, et al
    Unilateral magnetic resonance-guided focused ultrasound pallidotomy for Parkinson disease.
    Neurology. 2015 Jul 15. pii: 10.1212/WNL.0000000000001826.
    PubMed     Text format    


  174. KIM SJ, Udupa K, Ni Z, Moro E, et al
    Effects of subthalamic nucleus stimulation on motor cortex plasticity in Parkinson disease.
    Neurology. 2015 Jul 8. pii: 10.1212/WNL.0000000000001806.
    PubMed     Text format     Abstract available


  175. MARDER K, Wang Y, Alcalay RN, Mejia-Santana H, et al
    Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium.
    Neurology. 2015;85:89-95.
    PubMed     Text format     Abstract available


  176. SAFARPOUR D, Thibault DP, DeSanto CL, Boyd CM, et al
    Nursing home and end-of-life care in Parkinson disease.
    Neurology. 2015 Jul 2. pii: 10.1212/WNL.0000000000001715.
    PubMed     Text format     Abstract available


  177. XIE T, Guan R, Staisch J, Towle VL, et al
    Respiratory dyskinesia in a patient with Parkinson disease successfully treated with STN DBS.
    Neurology. 2015 Jul 2. pii: 10.1212/WNL.0000000000001809.
    PubMed     Text format    


    June 2015
  178. THOLFSEN LK, Larsen JP, Schulz J, Tysnes OB, et al
    Development of excessive daytime sleepiness in early Parkinson disease.
    Neurology. 2015 Jun 17. pii: 10.1212/WNL.0000000000001737.
    PubMed     Text format     Abstract available


  179. RACETTE BA, Willis AW
    Time to change the blind men and the elephant approach to Parkinson disease?
    Neurology. 2015 Jun 12. pii: 10.1212/WNL.0000000000001739.
    PubMed     Text format     Abstract available


  180. MULLER ML, Albin RL, Bohnen NI, Jennings D, et al
    Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study.
    Neurology. 2015;84:2292.
    PubMed     Text format    


  181. JENNINGS D, Siderowf A, Stern M, Seibyl J, et al
    Author Response.
    Neurology. 2015;84:2292.
    PubMed     Text format    


    May 2015
  182. GUSTAFSSON H, Nordstrom A, Nordstrom P
    Depression and subsequent risk of Parkinson disease: A nationwide cohort study.
    Neurology. 2015 May 20. pii: 10.1212/WNL.0000000000001684.
    PubMed     Text format     Abstract available


  183. BRIDEL C, Garibotto V
    Teaching NeuroImages: Drug-induced parkinsonism with asymmetrical putaminal DaT binding.
    Neurology. 2015;84:e159.
    PubMed     Text format    


  184. MCKEOWN MJ, Peavy GM
    Biomarkers in Parkinson disease: It's time to combine.
    Neurology. 2015 May 15. pii: 10.1212/WNL.0000000000001692.
    PubMed     Text format    


  185. CAMPBELL MC, Koller JM, Snyder AZ, Buddhala C, et al
    CSF proteins and resting-state functional connectivity in Parkinson disease.
    Neurology. 2015 May 15. pii: 10.1212/WNL.0000000000001681.
    PubMed     Text format     Abstract available


    March 2015
  186. WEINTRAUB D, Papay K, Xie SX
    Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.
    Neurology. 2015;84:1386-7.
    PubMed     Text format    


  187. LIANG JW, Shanker VL, Groves M
    Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.
    Neurology. 2015;84:1386-7.
    PubMed     Text format    


  188. MASSANO J, Troster AI
    About deep brain stimulation.
    Neurology. 2015;84:e100-1.
    PubMed     Text format    


  189. ANANG JB, Postuma R
    Author response.
    Neurology. 2015;84:1285-6.
    PubMed     Text format    


    February 2015
  190. MACKAY CE, Szewczyk-Krolikowski K, Ben-Shlomo Y, Hu M, et al
    Author response.
    Neurology. 2015;84:546.
    PubMed     Text format    


  191. MONTGOMERY EB JR
    Functional connectivity in the basal ganglia network differentiates PD patients from controls.
    Neurology. 2015;84:546.
    PubMed     Text format    


    January 2015
  192. FUHR P, Zimmermann R, Gschwandtner U
    Author response.
    Neurology. 2015;84:104-5.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: